We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liposomal bupivacaine: A long-acting local anesthetic for postsurgical analgesia.
- Authors
Massaro, Frank
- Abstract
More than 90 million surgical procedures are performed in the United States each year, and providing effective postsurgical pain management is a clinical imperative for every patient undergoing surgery. Infiltration of local anesthetic into the surgical site at closure provides temporary analgesia and is one aspect of the multimodal approach to postsurgical analgesia recommended in current guidelines. The duration of action of bupivacaine HCI and other available local anesthetics is limited, however, lasting 7 hours or less, and patients may experience breakthrough pain before they are able to take or tolerate oral analgesics, thus necessitating the use of strong parenteral analgesics (frequently opioids) in the immediate postsurgical period. A medical need exists to extend the pain relief supplied by bupivacaine HCI, thereby delaying, decreasing, and/or eliminating the potential need for opioids. A new formulation, bupivacaine liposome injectable suspension, is indicated for administration into the surgical site to produce postsurgical analgesia. After local infiltration of liposomal bupivacaine into soft tissue, bupivacaine is released from the multivesicular liposomes over a period of time, resulting in markedly prolonged plasma levels and analgesia. A single dose of liposomal bupivacaine is associated with both pain relief for 72 hours and a 45% reduction in total opioid consumption at 72 hours.
- Subjects
HEMORRHOIDS; INGUINAL hernia; BUNION; CLINICAL trials; DRUG interactions; FOOT surgery; LOCAL anesthetics; MEDICAL prescriptions; NARCOTICS; HEALTH outcome assessment; POSTOPERATIVE pain; TOTAL knee replacement; TREATMENT effectiveness; PHARMACODYNAMICS; SURGERY; THERAPEUTICS
- Publication
Formulary, 2012, Vol 47, Issue 6, p212
- ISSN
1082-801X
- Publication type
Article